Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) CFO Sells 4,338 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) CFO Brittany Bagley sold 4,338 shares of the company's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now directly owns 98,825 shares of the company's stock, valued at $37,449,733.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock traded up $22.80 on Thursday, hitting $384.51. The company's stock had a trading volume of 949,489 shares, compared to its average volume of 520,782. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $29.02 billion, a P/E ratio of 111.49, a price-to-earnings-growth ratio of 9.50 and a beta of 0.94. The firm has a fifty day moving average price of $335.53 and a 200-day moving average price of $313.10. Axon Enterprise, Inc. has a 52-week low of $189.12 and a 52-week high of $384.73.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same period in the previous year, the firm posted $0.80 EPS. The company's quarterly revenue was up 34.5% compared to the same quarter last year. On average, equities research analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Institutional Trading of Axon Enterprise

Several institutional investors and hedge funds have recently made changes to their positions in the stock. ING Groep NV lifted its holdings in Axon Enterprise by 9.3% in the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company's stock valued at $2,491,000 after purchasing an additional 821 shares in the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company's stock valued at $1,659,000 after buying an additional 40 shares during the period. GSA Capital Partners LLP acquired a new stake in Axon Enterprise during the first quarter worth approximately $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Axon Enterprise by 14.8% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company's stock worth $53,307,000 after acquiring an additional 22,013 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company's stock valued at $2,693,000 after acquiring an additional 1,634 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Robert W. Baird upped their price target on Axon Enterprise from $360.00 to $400.00 and gave the company an "outperform" rating in a report on Tuesday. Bank of America assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price objective for the company. Northland Securities boosted their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an "outperform" rating in a report on Thursday, August 8th. JMP Securities raised their price target on Axon Enterprise from $375.00 to $430.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Barclays raised their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.